MX2022011062A - Tratamientos para mejorar o disminuir el deterioro de la funcion mitocondrial. - Google Patents
Tratamientos para mejorar o disminuir el deterioro de la funcion mitocondrial.Info
- Publication number
- MX2022011062A MX2022011062A MX2022011062A MX2022011062A MX2022011062A MX 2022011062 A MX2022011062 A MX 2022011062A MX 2022011062 A MX2022011062 A MX 2022011062A MX 2022011062 A MX2022011062 A MX 2022011062A MX 2022011062 A MX2022011062 A MX 2022011062A
- Authority
- MX
- Mexico
- Prior art keywords
- heart failure
- impairment
- mitochondrial
- ejection fraction
- therapies
- Prior art date
Links
- 230000006735 deficit Effects 0.000 title abstract 2
- 230000004898 mitochondrial function Effects 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title 1
- 206010007558 Cardiac failure chronic Diseases 0.000 abstract 2
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 201000005943 Barth syndrome Diseases 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 206010014982 Epidermal and dermal conditions Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 201000002169 Mitochondrial myopathy Diseases 0.000 abstract 1
- 206010037075 Protozoal infections Diseases 0.000 abstract 1
- 208000004531 Renal Artery Obstruction Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 206010038378 Renal artery stenosis Diseases 0.000 abstract 1
- 206010063837 Reperfusion injury Diseases 0.000 abstract 1
- 238000002583 angiography Methods 0.000 abstract 1
- 208000016097 disease of metabolism Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000014617 hemorrhoid Diseases 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 abstract 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000004065 mitochondrial dysfunction Effects 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 230000004220 muscle function Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 210000002027 skeletal muscle Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Materials For Medical Uses (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
Abstract
Tratamientos con péptidos para mejorar o disminuir el deterioro de la función mitocondrial. Estos tratamientos se pueden utilizar para trastornos que producen, son producidos, contribuyen o están relacionados con la disfunción mitocondrial, tales como neurodegeneración, enfermedad metabólica, insuficiencia cardíaca congestiva, insuficiencia cardíaca crónica con fracción de eyección reducida, insuficiencia cardíaca crónica con fracción de eyección conservada, síndrome de Barth, enfermedad renal y insuficiencia renal debido a angiografía renal percutánea para estenosis de la arteria renal, función del músculo esquelético alterada en ancianos, miopatía mitocondrial muscular primaria y neuropatía, lesión por isquemia-reperfusión e infecciones por protozoos, neuropatía periférica, trastornos dermatológicos y hemorroides inflamadas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062986361P | 2020-03-06 | 2020-03-06 | |
| PCT/US2021/021171 WO2021178864A2 (en) | 2020-03-06 | 2021-03-05 | Treatments for improving or lessening impairment of mitochondrial function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022011062A true MX2022011062A (es) | 2022-09-21 |
Family
ID=77555308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022011062A MX2022011062A (es) | 2020-03-06 | 2021-03-05 | Tratamientos para mejorar o disminuir el deterioro de la funcion mitocondrial. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210275624A1 (es) |
| EP (1) | EP4114429A2 (es) |
| JP (1) | JP2023516431A (es) |
| KR (1) | KR20220151628A (es) |
| CN (1) | CN115605215A (es) |
| CA (1) | CA3170752A1 (es) |
| IL (1) | IL296239A (es) |
| MX (1) | MX2022011062A (es) |
| WO (1) | WO2021178864A2 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2504035B8 (en) * | 2009-11-10 | 2019-06-05 | Allegro Pharmaceuticals, LLC | Compositions and methods for inhibiting cellular adhesion or directing diagnostic or therapeutic agents to rgd binding sites |
| EP4003392A4 (en) * | 2019-07-26 | 2023-08-09 | Allegro Pharmaceuticals, LLC | PEPTIDES FOR THE TREATMENT OF NON-EXCESSIVE MACULAR DEGENERATION AND OTHER EYE DISEASES |
| KR20240060525A (ko) | 2024-04-03 | 2024-05-08 | 한국세라믹기술원 | 산화갈륨 박막 구조물, 이의 제조방법 및 이를 포함하는 포토다이오드 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994015953A1 (en) * | 1993-01-04 | 1994-07-21 | The Regents Of The University Of California | Platelet-specific therapeutic compound and method of treating platelet-mobilizing diseases |
| US9345739B2 (en) * | 2007-11-08 | 2016-05-24 | The General Hospital Corporation | Methods and compositions for the treatment of proteinuric diseases |
| WO2011022056A2 (en) * | 2009-08-18 | 2011-02-24 | Medical College Of Georgia Research Institute, Inc. | PEPTIDE MODULATORS OF THE δPKC INTERACTION WITH THE D SUBUNIT OF F1FO ATP SYNTHASE/ATPASE AND USES THEREOF |
| EP2504035B8 (en) * | 2009-11-10 | 2019-06-05 | Allegro Pharmaceuticals, LLC | Compositions and methods for inhibiting cellular adhesion or directing diagnostic or therapeutic agents to rgd binding sites |
| AU2012253511A1 (en) * | 2011-05-09 | 2014-01-09 | Allegro Pharmaceuticals, Inc. | Integrin receptor antagonists and their methods of use |
| WO2014059034A2 (en) * | 2012-10-09 | 2014-04-17 | President And Fellows Of Harvard College | Nad biosynthesis and precursors for the treatment and prevention of cancer and proliferation |
| CA3020393A1 (en) * | 2016-04-11 | 2017-10-19 | Carnot, Llc | Chiral peptides |
| US20180207227A1 (en) * | 2017-01-19 | 2018-07-26 | Allegro Pharmaceuticals, Inc. | Therapeutic and Neuroprotective Peptides |
| CN110945010A (zh) * | 2017-06-19 | 2020-03-31 | 急速制药有限责任公司 | 肽组合物和相关方法 |
| EP3642214A2 (en) * | 2017-06-19 | 2020-04-29 | Gangadhara Ganapati | Nicotinamide riboside derivatives and their uses |
| WO2019221959A1 (en) * | 2018-05-16 | 2019-11-21 | Peyman Gholam A | Method of treating, reducing, or alleviating a medical condition in a patient |
| WO2020074937A1 (en) * | 2018-10-09 | 2020-04-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of alpha-v-integrin (cd51) inhibitors for the treatment of cardiac fibrosis |
-
2021
- 2021-03-05 CA CA3170752A patent/CA3170752A1/en active Pending
- 2021-03-05 KR KR1020227032136A patent/KR20220151628A/ko unknown
- 2021-03-05 JP JP2022553111A patent/JP2023516431A/ja active Pending
- 2021-03-05 CN CN202180019336.0A patent/CN115605215A/zh active Pending
- 2021-03-05 IL IL296239A patent/IL296239A/en unknown
- 2021-03-05 WO PCT/US2021/021171 patent/WO2021178864A2/en unknown
- 2021-03-05 EP EP21764579.5A patent/EP4114429A2/en active Pending
- 2021-03-05 MX MX2022011062A patent/MX2022011062A/es unknown
- 2021-03-05 US US17/193,832 patent/US20210275624A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220151628A (ko) | 2022-11-15 |
| JP2023516431A (ja) | 2023-04-19 |
| CN115605215A (zh) | 2023-01-13 |
| WO2021178864A3 (en) | 2021-11-04 |
| IL296239A (en) | 2022-11-01 |
| EP4114429A2 (en) | 2023-01-11 |
| WO2021178864A2 (en) | 2021-09-10 |
| CA3170752A1 (en) | 2021-09-10 |
| US20210275624A1 (en) | 2021-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022011062A (es) | Tratamientos para mejorar o disminuir el deterioro de la funcion mitocondrial. | |
| RU2020119390A (ru) | Применение каннабиноидов при лечении приступов, связанных с синдромом леннокса-гасто | |
| PH12018501969A1 (en) | Pharmaceutical composition comprising empagliflozin and uses thereof | |
| CO2023008303A2 (es) | Derivados de ácido 4-(2-fluoro-4-metoxi-5-3-(((1-metilciclobutil)metil)carbamoil)biciclo[2.2.1]heptan-2-il)carbamoil)fenoxi)-1-metilciclohexano-1-carboxílico y compuestos similares como moduladores de rxfp1 para el tratamiento de insuficiencia cardíaca | |
| Xiang et al. | Natural plant products in treatment of pulmonary arterial hypertension | |
| Choi et al. | Decursin in Angelica gigas Nakai (AGN) enhances doxorubicin chemosensitivity in NCI/ADR‐RES ovarian cancer cells via inhibition of P‐glycoprotein expression | |
| Piskač et al. | Cardiotoxicity of yew | |
| CL2021000444A1 (es) | Métodos para reducir el riesgo de diabetes en pacientes tratados por enfermedades relacionadas con el colesterol alto. | |
| BR112017024975A2 (pt) | beta-caseína a2 e capacidade antioxidante | |
| CN104208054A (zh) | 大黄素在制备预防急性暴发性肝炎药物中的应用 | |
| Suresh | Hypovitaminosis D and COVID-19: matter of concern in India? | |
| SAITOH et al. | Effects of let ventricular systolic dysfunction and cardio-renal anemia syndrome on walking ability and Activities of Daily Living in patients with heart failure | |
| Scott et al. | Targeting the NLRP3 Inflammasome as a Novel Approach to Treat Pulmonary Hypertension | |
| Momomura | Harmonization between Pharmacotherapy and Non-pharmacotherapy | |
| Park et al. | A case study of hwa-byung has treated by autogen training | |
| Salas et al. | Impact of Post-Transplant Cyclophosphamide (PTCY)-Based Prophylaxis in Matched Sibling Donor Allo-HCT for Patients with Myelodysplastic Syndrome: A Study on Behalf of the Chronic Malignancies Working Party of the EBMT | |
| Yeary et al. | Outcome results of weight loss and maintenance trial in African American adults of faith | |
| Chambers et al. | Female Mice Are Resistant to Inward Remodeling of Parenchymal Arterioles Observed in Male Mice During Angiotensin II‐Induced Hypertension | |
| Tellor | Gastrointestinal haemorrhage, haemorrhagic stroke, melaena, nose bleed and haematuria: 11 case reports | |
| Wasserstrum | Amiodarone/ibrutinib interaction | |
| Chen | An overview of the effects of physical activity and exercise on cardiovascular disease Prevention | |
| Nelson | Prevalence of cardio-embolic event among patients with spontaneous echo contrast on transthoracic echocardiography (SMOCC-Heart Study). | |
| Kim et al. | Prevalence of childhood and adolescent obesity in Korea | |
| Van Buuren et al. | PM120 Electrical Myostimulation Improves Quality of Life, Left Ventricular Function and Peak Oxygen Consumption in Patients With Chronic Heart Failure-Results From the EMS Study Comparing Different Stimulation Strategies | |
| Pepper | Takotsubo cardiomyopathy: case report |